Effect of Irradiation on Tissue Penetration Depth of Doxorubicin after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Novel Ex-Vivo Model

Background: This study was performed to assess the impact of irradiation on the tissue penetration depth of doxorubicin delivered during Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC). Methods: Fresh post mortem swine peritoneum was cut into 10 proportional sections. Except for 2 control samples, all received irradiation with 1, 2, 7 and 14 Gy, respectively. Four samples received PIPAC 15 minutes after irradiation and 4 other after 24 hours. Doxorubicin was aerosolized in an ex-vivo PIPAC model at 12 mmHg/36°C. In-tissue doxorubicin penetration was measured using fluorescence microscopy on frozen thin sections. Results: Doxorubicin penetration after PIPAC (15 minutes after irradiation) was 476 ± 74 µm for the control sample, 450 ± 45µm after 1 Gy (p > 0.05), 438 ± 29 µm after 2 Gy (p > 0.05), 396 ± 32 µm after 7 Gy (p = 0.005) and 284 ± 57 after 14 Gy irradiation (p < 0.001). The doxorubicin penetration after PIPAC (24 hours after irradiation) was 428 ± 77 µm for the control sample, 393 ± 41 µm after 1 Gy (p > 0.05), 379 ± 56 µm after 2 Gy (p > 0.05), 352 ± 53 µm after 7 Gy (p = 0.008) and 345 ± 53 after 14 Gy irradiation (p = 0.001). Conclusions: Higher (fractional) radiation dose might reduce the tissue penetration depth of doxorubicin in our ex-vivo model. However, irradiation with lower (fractional) radiation dose does not affect the tissue penetration negatively. Further studies are warranted to investigate if irradiation can be used safely as chemopotenting agent for patients with peritoneal metastases treated with PIPAC.

[1]  M. Desvaux,et al.  Hyperspectral deep ultraviolet autofluorescence of muscle fibers is affected by postmortem changes. , 2015, Journal of agricultural and food chemistry.

[2]  Vladimir P Torchilin,et al.  Barriers to drug delivery in solid tumors , 2014, Tissue barriers.

[3]  Urs Giger-Pabst,et al.  Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.

[4]  M. Dutreix,et al.  Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept , 2011, Surgical Endoscopy.

[5]  W. Solass,et al.  Description of a novel approach for intraperitoneal drug delivery and the related device , 2011, Surgical Endoscopy.

[6]  P. Fracasso,et al.  Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. , 2011, Gynecologic oncology.

[7]  S. Bruin,et al.  8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer , 2008, Annals of Surgical Oncology.

[8]  M. Tan,et al.  Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. , 2007, International journal of radiation oncology, biology, physics.

[9]  M. Flessner,et al.  The transport barrier in intraperitoneal therapy. , 2005, American journal of physiology. Renal physiology.

[10]  F. Kwiatkowski,et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Mocellin,et al.  Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. , 2003, Surgical oncology clinics of North America.

[13]  P. Sugarbaker.  Carcinomatosis--is cure an option? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Faure,et al.  Peritoneal carcinomatosis from non‐gynecologic malignancies , 2000, Cancer.

[15]  P. Sugarbaker,et al.  Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. , 1996, Anti-cancer drugs.

[16]  James B. Smathers,et al.  Biologically effective dose distribution based on the linear quadratic model and its clinical relevance , 1995 .

[17]  J. Mcvie,et al.  Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. , 1989, Cancer research.

[18]  D. Elias,et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Jacquet,et al.  Peritoneal-plasma barrier. , 1996, Cancer treatment and research.

[20]  H. Withers,et al.  Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. , 1995, International journal of radiation oncology, biology, physics.

[21]  V. Devita,et al.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. , 1978, Cancer treatment reports.